Business Wire

Tetrate and Federal Agency NIST Cohost ZTA and DevSecOps Conference 2022 Kicking Off With Istio and Envoy Training

5.1.2022 16:07:00 EET | Business Wire | Press release

Share

Tetrate, the leading company providing a zero-trust application connectivity platform, announced their third annual conference on Zero Trust Architecture (ZTA) and DevSecOps for Cloud Native Applications in partnership with the U.S. National Institute of Standards and Technology (NIST), the federal organization responsible for creating security standards. The NIST–Tetrate multi-cloud conference is a premier event for CISOs, platform architects, and tech leadership from federal and corporate organizations.

The virtual conference will take place on January 27 from 8:00 a.m. – 5:00 p.m. EST and will be preceded by a 2.5-hour training on January 26, showcasing the implementation of Zero Trust Architecture on an actual Platform One deployment. This year’s conference will focus on DevSecOps and ZTA as foundational approaches to developing, deploying, and operating high assurance, cloud native applications. Featured speakers include: André Mendes, Department of Commerce CIO; Kelsey Hightower, Principal Engineer Google Cloud; Ronald Ross, NIST Fellow; and Zack Butcher, Tetrate Founding Engineer. The conference has seen tremendous growth in attendance over the past three years. Past speakers have included Nicolas Chalain, the U.S. Air Force’s first Chief Software Officer, and Zulfikar Ramzan, CTO of RSA Security.

“Cybersecurity incidents are one of the biggest issues facing organizations today, especially as the world moves towards cloud-native applications,” said David Ferraiolo of NIST. “Developing, deploying, and operating zero-trust enabled applications to achieve security, reliability, and resiliency is extremely important for organizations to feel secure.”

“Over the last three years, the NIST–Tetrate conference has featured dialogues and workshops from the world’s most esteemed service mesh and cybersecurity experts," said Varun Talwar, co-founder of Tetrate. "The growth in popularity of the conference is a testament to the importance of ZTA and DevSecOps in a multi-cloud environment. This year, again, we're thrilled to gather together and offer our global community valuable insights and perspectives from top visionaries."

Cloud-native applications often consist of microservices deployed across a combination of public cloud, private cloud, and on-prem, also known as heterogeneous infrastructure. This has created challenges related to connectivity, security, and reliability for delivering high-assurance applications, leading to the popularity of DevSecOps and ZTA. Service mesh plays a critical role in incorporating zero-trust design and DevSecOps principles by adding security and reliability to connect microservices across infrastructures without any additional code.

The conference will feature presentations by domain experts, practitioners, and thought leaders in DevSecOps and Zero Trust Architecture (ZTA) deployments, as well as demonstrations of proof-of-concept use cases in multi-cloud environments. Presentations will address the following:

  • ZTA guiding principles and approaches for workflow, system design, and operations through DevSecOps pipelines, authentication and authorization frameworks, and continuous monitoring;
  • NIST’s latest guidance on DevSecOps and security engineering practices;
  • The role of automation in operational security;
  • The benefits of prescribed approaches, such as prevention of configuration drift and continuous authority to operate.

In addition to a lineup of notable speakers, the training on January 26 will help deliver an educational experience where attendees will learn new skills and cover the deployment of a zero-trust platform with the use of Istio, Kubernetes, and other tools to implement the following security components:

  • in-app and user-level security permissions,
  • encryption in transit,
  • enhanced identity and access controls, and
  • runtime observability.

Tetrate also provides free passes, on request, to application security professionals who need the $35 fee waived.

Join the virtual event: Registration page

  • Join and follow the conversation with hashtag #ZTACon2022 #DevSecOps
  • Twitter: @tetrateio
  • LinkedIn: Tetrate
  • YouTube: Tetrate

For more information regarding ZTA and DevSecOps Conference 2022, an entirely virtual experience taking place this week, please visit: https://www.tetrate.io/zta-devsecops-conference-2022.

About Tetrate–NIST Collaboration

Tetrate and NIST have collaborated over the last three years across multiple deliverables. Using NIST’s experience with cybersecurity and Tetrate’s expertise on secure service mesh, they have collaborated to produce U.S. security standards for a distributed architecture:

About Tetrate

Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Customers get consistent, baked-in observability, runtime security, and traffic management in any environment. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Tetrate remains a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io.

About NIST

The National Institute of Standards and Technology (NIST) was founded by the U.S. Congress in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation's oldest physical science laboratories. From the smart electric power grid and electronic health records to atomic clocks, advanced nanomaterials, and computer chips, innumerable products and services today rely in some way on technology, measurement, and standards provided by NIST.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Annie Fink, Bospar
Annie@bospar.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye